Actusnews Wire - French company specializing in the dissemination of regulated information

  THERANEXUS company press release from 21/12/2022

  21/12/2022 - 18:00


Lyon, France – 21 December 2022 – 6:00pm CET - Theranexus, an innovative biopharmaceutical company innovating in the treatment of rare neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its financial communication agenda for 2023. Each publication will be released after Euronext market closing, unless otherwise specified. These dates are given as an indication, they are likely to be modified if necessary.

Indicative calendar

Events Dates
Cash position as at December 31th 2022 18 January 2023
(before stock exchange)
2022 Year-End Results and Cash position as at March 31th 2023 12 April 2023
Cash position as at June 30th 2023 11 July 2023
2023 Half-Year Results 28 September 2023
Cash position as at September 30th 2022  17 October 2023

About Theranexus

Theranexus is an innovative biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells.

The company has a unique platform for the identification and characterization of advanced therapy drug candidates targeting rare neurological disorders and an initial drug candidate in clinical development for Batten disease.
Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

More information at
Click and follow us on Twitter and Linkedln


Thierry Lambert

Chief Financial Officer

Théo Martin/Pierre Laurent

Investor Relations
+33 (0)1 44 71 94 97

Florence Portejoie

Media Relations
+ 33 (0)6 07 76 82 83

This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: lG9pY5ubZmyWy5psk8tnZmaZaJeXlZTIbWqZl2ObZcecm22UxpdqbpXLZnBonGlv
- Check this key:

  Original Source: THERANEXUS